NEW YORK STATE OF OPPORTUNITY. Department of Health

KATHY HOCHUL
Governor

JAMES V. McDONALD, M.D., M.P.H.
Commissioner

JOHANNE E. MORNE, M.S.
Executive Deputy Commissioner

Non-Patient-Specific Standing Order for the Administration of the Novavax COVID-19 Vaccine (2024-2025 Formula), for persons 12 years of age and older (Updated 9/17/2024)

Purpose: To reduce morbidity and mortality from COVID-19 by administering the Novavax COVID-19 Vaccine (2024-2025 Formula) as permitted by the policy and order sections of this Order. Pursuant to 8 NYCRR § 63.9, the Commissioner of Health is authorized to issue a statewide standing order where he finds that there is an outbreak of disease, or that there is imminent threat of an outbreak of disease.

Policy: Under this non patient-specific standing order, pharmacists who are employees, volunteers, and/or contractors of all pharmacies licensed in New York State and who are pharmacists authorized to administer vaccines pursuant to a certificate of administration from the Department of Education under non-patient specific orders in New York State and who are certified in cardio-pulmonary resuscitation, may administer the Novavax COVID-19 Vaccine (2024-2025 Formula), to individuals ages 12 years and older, as permitted by its Biologics License Application (BLA) approval or Emergency Use Authorization, as applicable, by the U.S. Food and Drug Administration (FDA), state and federal laws, Executive Orders, COVID-19 Public Health Readiness and Emergency Preparedness (PREP) Act declarations, and the recommendations of the Advisory Committee on Immunization Practices (ACIP).

The 2024–2025 Novavax formulation has been updated to a monovalent vaccine based on the Omicron JN.1 strain of SARS-CoV-2 and will be referred to as the "Novavax COVID-19 Vaccine (2024-2025 Formula)" in this standing order. This product is under Emergency Use Authorization.

Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) is no longer permitted to be used in any circumstance.

NOTE: Pharmacists and registered nurses must follow the requirements set forth in 8 NYCRR sections 63.9 & 64.7 respectively, including providing patients with requisite information, maintaining adequate records and adhering to reporting requirements.

Procedure: This standing order is for use of Novavax COVID-19 Vaccine (2024-2025 Formula) single dose vials for persons 12 years and older administered intramuscularly.

1. Assess individuals ages 12 years and above who *are NOT moderately to severely immunocompromised* for eligibility for Novavax COVID-19 Vaccine (2024-2025 Formula), based on the following criteria and administer dose(s) according to the table below:

COVID-19 Vaccination history§	Number of Novavax (2024-2025 Formula) doses indicated	Dosage (mL/ug)	Interval between doses
Unvaccinated	2	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	**Dose 1**: Day 0 **Dose 2**: 3-8 weeks after Dose 1*
1 or more doses any mRNA, NOT including 1 dose any 2024-2025 COVID-19 vaccine	1	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	At least 8 weeks after last dose
1 or more doses any mRNA, INCLUDING 1 dose any 2024-2025 COVID-19 vaccine	No further doses indicated		
1 dose any Novavax	1	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	**Dose 2**: 3-8 weeks after Dose 1*‡
2 or more doses any Novavax, NOT including 1 dose any 2024-2025 COVID-19 vaccine	1	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	At least 8 weeks after last dose
2 or more doses any Novavax, INCLUDING 1 dose any 2024-2025 COVID-19 vaccine	No further doses indicated		

Note: **People ages 65 years and older**: An additional dose of 2024–2025 COVID-19 vaccine is not currently recommended.

*An **8-week** interval between the first and second COVID-19 vaccine (Moderna, Novavax, and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

‡ If more than 8 weeks have elapsed since receipt of the first dose of Novavax, any 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) may be administered.

§People ages 18 years and older who received 1 or more doses of Janssen COVID-19 Vaccine, NOT including 1 dose of any 2024–2025 COVID-19 vaccine, should receive 1 dose of any 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) at least 8 weeks after the last dose.

For more information, please see CDC's Interim Clinical Considerations:
https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

2. Assess individuals aged 12 years and older who *are moderately to severely immunocompromised* and administer Novavax COVID-19 Vaccine (2024-2025 Formula) according to the table below:

COVID-19 Vaccination history †	**Number of Novavax COVID-19 (2024-2025 Formula) doses indicated**	**Dosage (mL/ug)**	**Interval between doses**
Unvaccinated	2	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	**Dose 1**: Day 0 **Dose 2**: 3 weeks after Dose 1 **See additional doses**
3 or more doses any Moderna or 3 or more doses any Pfizer-BioNTech, NOT including at least 1 dose any 2024-2025 COVID-19 vaccine	1	0.5 mL/50ug	At least 8 weeks after last dose **See additional doses**
3 or more doses and mRNA vaccine, INCLUDING at least 1 dose any 2024-2025 COVID-19 vaccine‡	**See additional doses**		
1 dose any Novavax	1	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	**Dose 2**: 3 weeks after Dose 1 **See additional doses**
2 or more doses any Novavax, NOT including 1 dose any 2024-2025 COVID-19 vaccine	1	0.5 mL/5 ug rS protein and 50 ug Matrix-M adjuvant	At least 8 weeks after last dose **See additional doses**
2 or more doses any Novavax, INCLUDING 1 dose any 2024-2025 COVID-19 vaccine	**See additional doses**		
ADDITIONAL DOSES: People in this age group may receive 1 additional dose of any 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech, regardless of the manufacturer for the initial series) at least 2 months following the last recommended 2024–2025 vaccine dose. Further additional doses may be administered, informed by the clinical judgment of a healthcare provider and personal preference and			

circumstances. Any further additional doses should be administered at least 2 months after the last 2024–2025 COVID-19 vaccine dose.

†People ages 18 years and older who received 1 or more doses of Janssen COVID-19 Vaccine, NOT including 1 dose of any 2024–2025 COVID-19 vaccine, should receive 1 dose of any 2024–2025 COVID-19 vaccine (i.e., Moderna, Novavax, or Pfizer-BioNTech) at least 8 weeks after the last dose. Additional doses may then be administered following the guidance in the table.

‡ This COVID-19 vaccine history refers to previous receipt of 3 doses of mRNA vaccine from the same manufacturer (i.e., Moderna or Pfizer-BioNTech) for initial vaccination followed by 1 or more additional doses of Moderna, Novavax, or Pfizer-BioNTech, excluding receipt of 2024–2025 vaccine for any previous doses.

Additional Clinical Considerations

- Novavax COVID-19 Vaccine (2024-2025 Formula) may be simultaneously administered with other routinely recommended vaccines. There are additional considerations for simultaneous administration of an orthopoxvirus vaccine and COVID-19 vaccine.
- Administration of COVID-19 vaccines should not be delayed in patients taking immunosuppressive therapies. Whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy.
- Revaccinate persons who received doses of COVID-19 vaccine prior to or during hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T-cell) therapy, following the current COVID-19 vaccination schedule. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy. For additional details and all clinical considerations, see Interim Clinical Considerations for Use of COVID-19 Vaccines

3. Screen for contraindications and precautions

   a. **Contraindications:** History of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of Novavax COVID-19 vaccine or to a component of the Novavax COVID-19 vaccine.

   b. **Precautions:**
      i. A diagnosed non-severe allergy to a component of the COVID-19 vaccine.
      ii. Non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of COVID-19, if receiving the same vaccine type
      iii. Multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A).
      iv. Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine.
      v. Moderate to severe illness with or without fever.

4. Provide information on the Novavax COVID-19 Vaccine (2024-2025 Formula) and obtain consent.

a. Prior to vaccine administration:

i. Inform each patient or a patient's legal guardian, as applicable, of the risks, benefits, and alternatives of receiving the Novavax COVID-19 Vaccine (2024-2025 Formula).

ii. As the vaccination provider, you must communicate to the recipient or their caregiver, information consistent with the information for recipients and caregivers prior to the individual receiving Novavax COVID-19 Vaccine (2024-2025 Formula) including: **(1)** FDA has issued an Emergency Use Authorization for use of the Novavax COVID-19 Vaccine (2024-2025 Formula). **(2)** The recipient or their caregiver has the option to accept or refuse Novavax COVID-19 Vaccine (2024-2025 Formula); **(3)** The significant known and potential risks and benefits of Novavax COVID-19 Vaccine, and the extent to which such risks and benefits are unknown; and **(4)** Information about available alternative vaccines and the risks and benefits of those alternatives.

iii. Obtain consent to administer the vaccine from the patient or the patient's legal guardian, as applicable. [Insert how the Organization will be documenting consent and what forms will be used].

iv. Provide written instructions to the parent or legal guardian regarding appropriate course of action in the event of adverse reactions.

v. Provide necessary information on receiving the next dose of vaccine, if applicable.

5. Prepare to administer vaccine

a. The Novavax COVID-19 Vaccine, Adjuvanted is a colorless to slightly yellow, clear to mildly opalescent suspension.

b. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer the vaccine if either of these conditions exist.

c. Visually assess patient weight and select a needle for vaccine administration based on the following chart:

Patient Gender	Patient Weight	Needle Length
Female	< 130 lbs	5/8* – 1"
	130–152 lbs	1"
	153–200 lbs	1–1½"
	200+ lbs	1½"
Male	< 130 lbs	5/8* – 1"
	130–152 lbs	1"
	153–260 lbs	1–1½"
	260+ lbs	1½"

*Some experts recommend a 5/8-inch needle for men and women who weigh less 130 pounds. If used, skin must be stretched tightly (**do not bunch subcutaneous tissue**).

6. Administer vaccine:
    a. Choose the correct needle gauge, needle length and injection site.
    b. Administer Novavax COVID-19 Vaccine (2024-2025 Formula) by intramuscular injection: 0.5mL

    Administer the Novavax COVID-19 Vaccine (2024-2025 Formula) in the deltoid muscle via the intramuscular (IM) route. Alternately, the anterolateral thigh can be used. A 1.5-inch needle is typically used for adults if administering vaccine in this site. More information about choice of needle length can be found at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html#t6_2

7. Document vaccination

    Document each patient's vaccine administration information and follow-up in the following places:

    i. **Medical Record System (including CDMS, as applicable) :** Ensure that the patient's name, the date the vaccine was administered, the name of the vaccine, the manufacturer and lot number, the vaccination site and route, address of administering site, and the name and title of the authorized person administering the vaccine, and the date it was given to the patient is documented in the patient's medical record or on a separate form retained by the authorized vaccinator who has administered the immunization, and in a retrievable format available to the State Education Department and the patient. If vaccine was not administered, record the reason(s) for non-receipt of the vaccine (e.g., medical contraindication, refusal). Documentation must be completed within 24 hours of administration. This information, whether in a medical record or separately kept, must be recorded and maintained in accordance with 8 NYCRR § 29.2 (a) (3).

    ii. Signed Certificate of Immunization (given to the patient): Record the patient's name, date of vaccination, name/location of the administering pharmacy, administering pharmacist, name of vaccine, manufacturer and lot number, and recommendations for future immunizations.

    iii. **New York State Immunization Information System (NYSIIS) and City Immunization Registry (CIR):** Report all doses administered to those 18 years of age and younger to NYSIIS or CIR within 14 days of administration. Report all doses administered to those 19 years of age and older to NYSIIS and CIR after obtaining consent. With respect to NYSIIS, if the dose was documented in the Countermeasure Data Management System (CDMS), then the NYSDOH shall transmit data from CDMS to NYSIIS for all patients ages 18 and younger and for those who are 19 and older, with consent.

8. Management of medical emergencies

    A post vaccination observation period should be considered to monitor patients for the occurrence of immediate adverse reactions:

- 30 minutes:
    - History of non-severe, immediate (less than 4 hours) allergic reaction after a previous dose of COVID-19 vaccine,

- History of an allergy-related contraindication to a different type of COVID-19 vaccine History of anaphylaxis after non-COVID-19 vaccines or injectable therapies

- 15 minutes: All other people, particularly when vaccinating adolescents

Be prepared for management of a medical emergency related to the administration of vaccine by maintaining written copies of the standing orders and protocols for administration of epinephrine and diphenhydramine. RNs and pharmacists shall be responsible for having emergency anaphylaxis treatment agents, related syringes and needles at the immunization site, including at least 3 epinephrine prefilled syringes or autoinjectors, H1 antihistamine, blood pressure cuff, and a stethoscope and timing device to assess pulse. To prevent syncope, vaccinate patients while they are seated or lying down and assess for signs of syncope such as extreme paleness, sweating, coldness of the hands and feet, nausea, lightheadedness, dizziness, weakness or visual disturbances. For more information, please see:

i. Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination sites at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html
ii. CDC 's General Best Practice Guidelines for Immunization, "Preventing and Managing Adverse Reactions," at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/adverse-reactions.pdf
iii. Immunization Action Coalition's "Medical Management of Vaccine Reactions in Adults in a Community Setting" at https://www.immunize.org/catg.d/p3082.pdf.
iv. Immunization Action Coalition's "Medical Management of Vaccine Reactions in Children and Teens in a Community Setting" at https://www.immunize.org/catg.d/p3082a.pdf

9. Reporting of adverse events
   a. Report the following information associated with the administration of Novavax COVID-19 vaccine (2024-2025 Formula) of which they become aware to Vaccine Adverse Events Electronic Reporting System (VAERS) in accordance with the "Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers)," including:
      i. Vaccine administration errors whether or not associated with an adverse event
      ii. Serious adverse events (irrespective of attribution to vaccination)
      iii. Cases of myocarditis or pericarditis after vaccine
      iv. Cases of Multisystem Inflammatory Syndrome in children and adults
      v. Cases of COVID-19 that result in hospitalization or death
      vi. Any additional adverse events and revised safety requirements per the Food and Drug Administration's approval
   b. Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967.
10. Storage and Handling of Vaccine for Novavax COVID-19 Vaccine (2023-2024 Formula)
   a. For storage and handling details please see the "Factsheet for Healthcare Providers" located at: https://www.fda.gov/media/159897/download?attachment

Order: I am hereby prescribing this non-patient-specific order to administration of Novavax COVID-19 Vaccine (2024-2025 Formula). Specifically, pharmacists who are employees, volunteers, or contractors of a pharmacy licensed in New York State may administer Novavax COVID-19 Vaccine, as permitted by its BLA approval or its Emergency Use Authorization (EUA), as applicable, state and federal laws, Executive Orders, COVID-19 Public Health Readiness and Emergency Preparedness (PREP) Act declarations, ACIP recommendations, and the CDC's and New York State's Vaccination Program.

This non patient-specific order shall remain in effect for the vaccination of any individuals as set forth herein, beginning on September 19, 2024 through December 31, 2024. In the event that I discontinue this non patient-specific order prior to December 31, 2024, notice of such discontinuance shall be provided to those employees, volunteers, and contractors of the pharmacy licensed in New York State permitted to execute under this Order using the usual methods of communication.

Signature: 

Date: September 19, 2024

Name of Physician: James V. McDonald MD MPH

Title: Commissioner

Institution: New York State Department of Health

NYS License No.: 186383

Effective Date of Order: September 19, 2024

Medicaid No: 07693570

NPI: 1619966959